Deniz Vaizoglu
UCL Institute of Neurology
5 Papers
Deniz Vaizoglu is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Biology & Protein degradation. The author has co-authored 1 publications.
Chat about Author
Papers
PolyGR and polyPR knock-in mice reveal a conserved neuroprotective extracellular matrix signature in C9orf72 ALS/FTD neurons
Carmelo Milioto,Mireia Carcolé,Rachel Coneys,Olivia N. Attrebi,Mhoriam Ahmed,Samuel Harris,Byung Il Lee,Meng-qing Yang,Raja Sekhar Nirujogi,Daniel Biggs,Sally Salomonsson,Matteo Zanovello,Eszter Katona,Idoia Glaria,Alla Mikheenko,Bethany Geary,Evan Udine,Deniz Vaizoglu,Rosa Rademakers,Marka van Blitterswijk,Anny Devoy,Soyon Youngae Hong,Linda Partridge,Pietro Fratta,Dario R. Alessi,Ben Davies,Marc Aurel Busche,Linda Greensmith,Elizabeth M. C. Fisher,Adrian M. Isaacs +29 more
TL;DR: In this article , a GGGGCC repeat expansion in C9orf72 is the most common genetic cause of ALS and FTD (C9ALS/FTD), but their most relevant effects in a physiological context are not known.
3
CRISPR/Cas9-mediated generation of a de novo C9ORF72 knock-in isogenic iPSC cell bank to model ALS and FTD
Niamh O’Brien,Erin C. Hedges,Remya R. Nair,AJ Cammack,M. Carcolé,Deniz Vaizoglu,Sara Tacconelli,Katie Sutherland,Chloe L. Fisher-Ward,A. R. Awan,Simon Topp,Alfredo Iacoangeli,A. Isaacs,Thomas J. Cunningham,Marc-David Ruepp,Sarah Mizielinska +15 more
A multimodal screening platform for endogenous dipeptide repeat proteins in C9orf72 patient iPSC neurons.
Benedikt V. Hölbling,Yashica Gupta,Paolo M. Marchi,Magda L. Atilano,Michael Flower,Enric Ureña,Rajkumar A. Goulden,Hannah K. Dobbs,Eszter Katona,A. Mikheenko,A. Giblin,Ali Raza Awan,Chloe L. Fisher-Ward,Niamh O’Brien,Deniz Vaizoglu,Liam Kempthorne,Lauren M. Gittings,M. Carcolé,Marc-David Ruepp,Sarah Mizielinska,Linda Partridge,P. Fratta,Sarah J Tabrizi,Bhuvaneish T. Selvaraj,Siddharthan Chandran,Emma Armstrong,Paul Whiting,Adrian M. Isaacs +27 more
C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation.
Nausicaa Valentina Licata,Riccardo Cristofani,Sally Salomonsson,Katherine M. Wilson,Liam Kempthorne,Deniz Vaizoglu,Vito Giuseppe D'Agostino,Daniele Pollini,Rosa Loffredo,Michael Pancher,Valentina Adami,Paola Bellosta,Antonia Ratti,Gabriella Viero,Alessandro Quattrone,Adrian M. Isaacs,Angelo Poletti,Alessandro Provenzani +17 more
TL;DR: In this paper, the authors developed a high-throughput drug screen for the identification of positive and negative modulators of dipeptide-repeat proteins (DPRs) levels.
Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo
Liam Kempthorne,Deniz Vaizoglu,Alexander J. Cammack,M. Carcolé,Pacharaporn Suklai,Bhavana Muralidharan,François Kroll,Thomas G. Moens,Lidia Yshii,Stijn Verschoren,Benedikt V. Hölbling,Eszter Katona,A. Mikheenko,R. Coneys,Paula de Oliveira,Yongjie Zhang,Karen Jansen,Lillian M. Daughrity,Alexander McGown,Tennore Ramesh,Ludo Van Den Bosch,Ahad A. Rahim,Leonard Petrucelli,Jason Rihel,Adrian M. Isaacs +24 more
TL;DR: It is shown that CRISPR-Cas13d originating from Ruminococcus flavefaciens (CasRx) can successfully reduce C9orf72 sense and antisense repeat transcripts and DPRs to background levels in HEK cells overexpressing C9orf72 repeats, highlighting the potential for RNA-targeting CRISPR systems as therapeutics for C9orf72 ALS/FTD.